Hypha Labs' Revolutionary Psilocybin Bioreactor Nominated for Best New Product of 2024 by Santa Monica Daily Press
Hypha Labs, Inc. (OTC PINK:DIGP), a leader in functional mushroom sciences, has received a prestigious nomination for its proprietary bioreactor. The Santa Monica Daily Press (SMDP) has nominated the device as the "Best New Product of 2024". This innovative bioreactor allows for the production of specialized mushroom ingredients, including psilocybin.
The SMDP article praises the bioreactor as a "groundbreaking technological advancement" in psilocybin mushroom production. It highlights the potential wide-ranging impact on the scientific community, mental health system, and consumers. Hypha Labs' CEO, Stone Douglass, expressed honor at the recognition and emphasized the company's commitment to bringing a revolutionary device to market as they prepare for a full commercial launch in the coming months.
Hypha Labs, Inc. (OTC PINK:DIGP), un leader nelle scienze dei funghi funzionali, ha ricevuto una prestigiosa nomination per il suo bioreattore proprietario. Il Santa Monica Daily Press (SMDP) ha nominato il dispositivo come il "Miglior Nuovo Prodotto del 2024". Questo innovativo bioreattore consente la produzione di ingredienti specializzati a base di funghi, inclusa la psilocibina.
L'articolo del SMDP elogia il bioreattore come un "avanzamento tecnologico rivoluzionario" nella produzione di funghi psilocibini. Sottolinea il potenziale impatto significativo sulla comunità scientifica, sul sistema di salute mentale e sui consumatori. Il CEO di Hypha Labs, Stone Douglass, ha espresso onore per il riconoscimento e ha sottolineato l'impegno dell'azienda a portare sul mercato un dispositivo rivoluzionario mentre si preparano per un lancio commerciale completo nei prossimi mesi.
Hypha Labs, Inc. (OTC PINK:DIGP), líder en ciencias de hongos funcionales, ha recibido una prestigiosa nominación por su biorreactor patentado. El Santa Monica Daily Press (SMDP) ha nominado el dispositivo como el "Mejor Nuevo Producto de 2024". Este innovador biorreactor permite la producción de ingredientes especiales de hongos, incluyendo la psilocibina.
El artículo del SMDP elogia el biorreactor como un "avance tecnológico revolucionario" en la producción de hongos psilocibina. Destaca el impacto potencial significativo en la comunidad científica, en el sistema de salud mental y en los consumidores. El CEO de Hypha Labs, Stone Douglass, expresó su honor por el reconocimiento y enfatizó el compromiso de la empresa para llevar al mercado un dispositivo revolucionario mientras se preparan para un lanzamiento comercial completo en los próximos meses.
하이파 랩스(Hypha Labs, Inc. (OTC PINK:DIGP))는 기능성 버섯 과학의 선도업체로, 독자적인 바이오리액터에 대한 권위 있는 후보에 올랐습니다. 산타모니카 데일리 프레스(Santa Monica Daily Press, SMDP)는 이 장치를 "2024년 최고의 신제품"으로 후보 지명했습니다. 이 혁신적인 바이오리액터는 실로시빈을 포함한 전문 버섯 재료의 생산을 가능하게 합니다.
SMDP 기사는 이 바이오리액터를 실로시빈 버섯 생산에 있어 "획기적인 기술 발전"으로 칭찬했습니다. 이는 과학 공동체, 정신 건강 시스템 및 소비자에 대한 광범위한 잠재적 영향을 강조합니다. 하이파 랩스의 CEO인 스톤 더글라스는 이 인정을 받아 영광스럽게 생각하며, 앞으로 몇 달 내에 본격적인 상용화를 위해 혁신적인 장치를 시장에 출시할 것이라는 회사의 약속을 강조했습니다.
Hypha Labs, Inc. (OTC PINK:DIGP), un leader dans les sciences des champignons fonctionnels, a reçu une nomination prestigieuse pour son bioréacteur propriétaire. Le Santa Monica Daily Press (SMDP) a nommé cet appareil comme le "Meilleur Nouveau Produit de 2024". Ce bioréacteur innovant permet la production d'ingrédients spécialisés à base de champignons, y compris la psilocybine.
L'article du SMDP loue le bioréacteur comme un "avancement technologique révolutionnaire" dans la production de champignons psilocybine. Il souligne l'impact potentiel étendu sur la communauté scientifique, le système de santé mentale et les consommateurs. Le PDG de Hypha Labs, Stone Douglass, a exprimé son honneur pour cette reconnaissance et a souligné l'engagement de l'entreprise à commercialiser un dispositif révolutionnaire tout en se préparant pour un lancement commercial complet dans les mois à venir.
Hypha Labs, Inc. (OTC PINK:DIGP), ein führendes Unternehmen in der funktionellen Pilzwissenschaft, hat eine prestigeträchtige Nominierung für seinen eigenen Bioreaktor erhalten. Die Santa Monica Daily Press (SMDP) hat das Gerät als "Bestes Neues Produkt 2024" nominiert. Dieser innovative Bioreaktor ermöglicht die Produktion von spezialisierten Pilzzutaten, einschließlich Psilocybin.
Der Artikel der SMDP lobt den Bioreaktor als "bahnbrechenden technologischen Fortschritt" in der Psilocybin-Pilzproduktion. Er hebt die potenziell weitreichenden Auswirkungen auf die wissenschaftliche Gemeinschaft, das psychische Gesundheitssystem und die Verbraucher hervor. Stone Douglass, CEO von Hypha Labs, äußerte sich geehrt über die Anerkennung und betonte das Engagement des Unternehmens, ein revolutionäres Gerät auf den Markt zu bringen, während sie sich auf einen umfassenden kommerziellen Launch in den kommenden Monaten vorbereiten.
- Nomination for "Best New Product of 2024" by Santa Monica Daily Press
- Proprietary bioreactor technology for producing specialized mushroom ingredients
- Potential impact on scientific community, mental health system, and consumers
- Preparing for full commercial launch in the coming months
- None.
LAS VEGAS, NV / ACCESSWIRE / July 31, 2024 / Hypha Labs, Inc. (OTC PINK:DIGP), a pioneer in functional mushroom sciences, is pleased to announce that the Company's proprietary bioreactor which allows individuals and companies to produce specialized mushroom ingredients such as psilcybin, has been nominated as "Best New Product of 2024" by the Santa Monica Daily Press (SMDP).
A prototype of the Hypha Labs bioreactor
In the article, the Santa Monica Daily Press refers to Hypha Lab's flagship product, lauding its "groundbreaking technological advancement in the landscape and production of psilocybin mushrooms."
The article goes on to note Hypha Lab's potential impact on society, stating "As Hypha Labs continues to innovate, the potential benefits of the bioreactor will likely be felt far and wide, impacting the scientific community, mental health system, and consumers in need."
"We are honored to be acknowledged by an important voice in the Santa Monica Daily Press," stated Stone Douglass, CEO, Hypha Labs. "We are still at the very beginning of our journey as we prepare a full commercial launch in the coming months and accolades such as this from independent voices are important to our team and to potential partners."
"And it is important as we roll-out what I firmly believe is a revolutionary device that's looking to change so much in a revolutionary industry to be worthy of this high praise," added Douglass. "I can tell you that we are doing our level best to bring to market the most convenient, reliable and effective at-home producer of mushroom ingredients that this industry, that this wellness movement, has ever seen."
The article is available in full at the following link:
About Hypha Labs, Inc.
The company has developed revolutionary cutting-edge technology focused on new methods of producing the active ingredients found in functional mushrooms such as psilocybin using its patent-pending bioreactor design. The Company has positioned itself to play an important role in the burgeoning Functional Mushroom industry in addition to being a disruptive force in the psilocybin space which is quickly manifesting into a similar pattern that was seen in the Cannabis Industry both from a medical and recreational usage with several states and cities have now decriminalized it use. Visit us at HyphaLabs.com.
SAFE HARBOR FORWARD LOOKING STATEMENTS:
This press release may contain forward looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
From time to time, the Company may post new and material information on its website or through its social media profiles at the links below:
LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs
For more information about Hypha Labs visit HyphaLabs.com
Investor and Media Relations:
Integrity Media Inc.
(888) 216-3595
team@integritymedia.com
Contact Information
Kurt Divich
President, Integrity Media Inc.
team@integritymedia.com
(888) 216-3595
SOURCE: Hypha Labs
View the original press release on accesswire.com
FAQ
What product has Hypha Labs (DIGP) been nominated for in 2024?
When is Hypha Labs (DIGP) planning to launch its bioreactor commercially?
What are the potential applications of Hypha Labs' (DIGP) bioreactor?
Who is the CEO of Hypha Labs (DIGP)?
